

Clinical Data's Cogenics Division Launches CogenicsOnline, a Global Personalized E-Commerce Solution for the Life Sciences Industry

Newton, MA, USA - February 11th, 2009 - Clinical Data, Inc. (NASDAQ: CLDA) announces today that its Cogenics division, the global leader in outsourced genomics services, has launched CogenicsOnline (<http://www.cogenicsonline.com>), a personalized global e-commerce solution for the life sciences industry.

CogenicsOnline offers e-commerce services to its growing customer base in the healthcare and life science industries, as well as agricultural and academic partners. The online solution allows customers to obtain express sequencing and order other high-value services, including gene expression, genotyping and biomanufacturing support.

Customers will benefit from personalized, online access, enabling them to place their order in their 'preferred' way, supplement the order with additional pre and post treatment services, track the order processing status and grant levels of access to results in different electronic formats.

"We are very pleased to provide our customers with this unique and secure online system which is based on several years of hands-on experience with our French web service, Gexbyweb," said Paul Tomlin, Senior Vice President European Operations and Finance, Cogenics. "This new portal is a key step toward expanding our leadership position in the Express sequencing markets both in Europe and the U.S. It is also an integral part of the Company's strategy to offer the same highest quality genomic services in a cost-effective and more efficient manner, wherever these services are performed."

CogenicsOnline is available immediately in the United Kingdom and France, with initial online ordering capabilities for express sequencing. Cogenics plans to extend its online service geographically to include other European countries in the coming months, and will include the United States during the course of 2009. In addition, Cogenics intends to broaden the range of services that will be available to customers online in parallel with the geographic expansion.

Cogenics provides next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Cogenics has two facilities in the USA - North Carolina and Texas, as well as in the United Kingdom, France and Germany.

About Cogenics

Cogenics, a division of Clinical Data, Inc., has established itself as a leading provider of value-based genomics solutions for both the Healthcare and the Life Sciences industries. These solutions span the areas of current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Cogenics customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies.

For more information, please visit <http://www.cogenics.com>.

About Clinical Data, Inc.

Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, *From Targeted Science to Better Healthcare*(R). The Company's PGxHealth(R) division is utilizing its proprietary portfolio of biomarkers to develop and commercialize a broad range of targeted therapeutics as well as pharmacogenetic tests that help predict drug safety and efficacy, thereby reducing health care costs. Its Cogenics(R) division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. To learn more, please visit the Company's website at <http://www.clda.com>.

For more information about Cogenics and its genomic services offerings, please call:

- For UK: +44 (0) 1279 873 837
- For France: +33 (0) 456 381 102
- For Germany: +49 (0) 815 899 85 77
- For the US +01 877 226 4364

or email sales@cogenics.com

CONTACT INFORMATION:

For further information, please contact:

Andrew Lloyd & Associates

Andrew Lloyd / Neil Hunter

Tel: +44 1273 675100

allo@ala.com / neil@ala.com

Theresa McNeely

Vice President

Corporate Communications

Clinical Data, Inc.

Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, our ability to successfully introduce our new products and services; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our Cogenics services will gain wide acceptance in the market; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for Cogenics' services; changes in government regulations, and changing relationships with customers, payers, suppliers and strategic partners; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof. Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2008, Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2008, and Current Reports on Form 8-K filed from time to time by the Company.